Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9510934 | 0.76 | ANPEP (0.39) | ANPEPSLC18A3 | |
| SCHEMBL4518955 | 0.74 | PNMT (0.39) | PNMT | |
| SCHEMBL4407901 | 0.71 | ANPEP (0.33) | ANPEPMEN1KMT2A | |
| SCHEMBL6962983 | 0.71 | ANPEP (0.33) | ANPEPMEN1KMT2A | |
| SCHEMBL4513001 | 0.67 | IDO1 (0.32) | PNMT | |
| SCHEMBL20063792 | 0.65 | ANPEP (0.56) | ANPEPSLC18A3 | |
| SCHEMBL1990443 | 0.65 | ANPEP (0.56) | ANPEPSLC18A3 | |
| SCHEMBL1990446 | 0.65 | ANPEP (0.56) | ANPEPSLC18A3 | |
| SCHEMBL29687690 | 0.65 | ANPEP (0.56) | ANPEPSLC18A3 | |
| SCHEMBL20095994 | 0.65 | ANPEP (0.56) | ANPEPSLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | PNMT 1875/4885ANPEP 815/4885SLC18A3 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.